Literature DB >> 19445740

HIV infection.

Martin Talbot1.   

Abstract

INTRODUCTION: Infection with the human immunodeficiency virus (HIV) usually leads to 8-10 years of asymptomatic infection before immune function deteriorates and AIDS develops. Without treatment, about 50% of infected people will die of AIDS over 10 years. With treatment, prognosis depends on age, CD4 cell count, and initial viral load. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of preventive interventions? What are the effects of different antiretroviral drug treatment regimens in HIV infection? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 17 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: combination treatments containing either CCR5 inhibitors or fusion inhibitors; early diagnosis and treatment of sexually transmitted diseases (STDs); early and delayed antiretroviral treatment using triple antiretroviral regimens; non-nucleoside reverse transcriptase inhibitor (NNRTI) based triple regimens; nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor-based triple regimens (standard, and boosted); post-exposure prophylaxis in healthcare workers; and presumptive mass treatment of sexually transmitted diseases (STDs).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19445740      PMCID: PMC2907940     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  33 in total

1.  Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.

Authors:  P Barreiro; V Soriano; F Blanco; C Casimiro; J J de la Cruz; J González-Lahoz
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

Review 2.  When should antiretroviral therapy for HIV be started?

Authors:  Andrew N Phillips; Brian G Gazzard; Nathan Clumeck; Marcelo H Losso; Jens D Lundgren
Journal:  BMJ       Date:  2007-01-13

Review 3.  Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.

Authors:  Roger Chou; Rongwei Fu; Laurie Hoyt Huffman; P Todd Korthuis
Journal:  Lancet       Date:  2006-10-28       Impact factor: 79.321

4.  Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Authors:  S Staszewski; P Keiser; J Montaner; F Raffi; J Gathe; V Brotas; C Hicks; S M Hammer; D Cooper; M Johnson; S Tortell; A Cutrell; D Thorborn; R Isaacs; S Hetherington; H Steel; W Spreen
Journal:  JAMA       Date:  2001-03-07       Impact factor: 56.272

5.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

Authors:  A Carr; K Samaras; A Thorisdottir; G R Kaufmann; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

6.  The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.

Authors:  T L Katzenstein; O Kirk; C Pedersen; J D Lundgren; H Nielsen; N Obel; C Nielsen; L R Mathiesen; J Gerstoft
Journal:  J Infect Dis       Date:  2000-08-03       Impact factor: 5.226

7.  Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; O Rouviere; F Bruno; R Avellaneda; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

8.  Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry.

Authors:  S A Wang; A L Panlilio; P A Doi; A D White; M Stek; A Saah
Journal:  Infect Control Hosp Epidemiol       Date:  2000-12       Impact factor: 3.254

9.  Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers.

Authors:  P D Ghys; M O Diallo; V Ettiègne-Traoré; G A Satten; C K Anoma; C Maurice; J C Kadjo; I M Coulibaly; S Z Wiktor; A E Greenberg; M Laga
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

10.  Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.

Authors:  C Michelet; A Ruffault; V Sébille; C Arvieux; P Jaccard; F Raffi; C Bazin; J M Chapplain; J P Chauvin; E Dohin; F Cartier; E Bellissant
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.